摘要
目的对中药治疗特发性肺纤维化系统评价/Meta分析进行再评价研究,以期为临床医师及研究者提供更科学的决策支持。方法检索中药治疗特发性肺纤维化系统评价/Meta分析的文献,筛选文献后提取资料,采用AMSTAR2(A Measurement Tool To Assess Systematic Reviews 2)量表和GRADE(Grade of Recommendation,Assessment,Development,and Evaluation)系统工具进行评估。结果共纳入14篇文献,106次结局指标;AMSTAR2量表结果示3篇属于低质量,11篇属于极低质量;GRADE分级显示,10次结局指标证据质量等级中等,83次等级低,13次等级极低。结论中药治疗特发性肺纤维化系统评价/Meta分析的方法学质量为低、极低,结局指标的证据质量等级多为低,高质量、证据强度高级别的系统评价亟需开展,从而作为高级别证据来指导临床。
Objective To reevaluate the systematic reviews/meta-analysis of Chinese medicinals for idiopathicpulmonary fibrosis to provide more scientific decision support for clinicians and researchers.Methods The systematicreviews/meta-analysis of Chinese herbal medicine for idiopathic pulmonary fibrosis were searched,and the data wereextracted after literature screening,using the AMSTAR2(A Measurement Tool To Assess Systematic Reviews 2)scaleand the GRADE(Grade of(A Measurement Tool To Assess Systematic Reviews 2)scale and the GRADE ofRecommendation,Assessment,Development,and Evaluation(GRADE)systematic tool were used to evaluate.ResultsA total of 14 publications with 106 outcome indicators were included;the results of AMSTAR2 scale showed that 3 wereof low quality and 11 were of very low quality;GRADE showed that 10 outcome indicators were of moderate quality ofevidence,83 were of low grade,and 13 were of very low grade.Conclusion The methodological quality of systematicevaluation/Meta-analysis of Chinese medicine for idiopathic pulmonary fibrosis was low and very low,and the evidencequality grade of outcome indicators was mostly low;systematic evaluation with high quality and high evidence strength isurgently needed so that it can be used as high-level evidence to guide clinical practice.
作者
王露
张海龙
张东
郭雯
李建生
Wang Lu;Zhang Hailong;Zhang Dong;Guo Wen;Li Jiansheng(Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan&Education Ministry of P.R,Henan University of Chinese Medicine,Zhengzhou 450046,China;The First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450003,China)
出处
《世界科学技术-中医药现代化》
CSCD
北大核心
2021年第4期988-997,共10页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
河南省高等学校青年骨干教师培养计划(2019GGJS107):抗纤缓急颗粒治疗特发性肺纤维化急性加重的疗效及对炎症反应的影响,负责人:张海龙
河南省特色学科中医学学科建设项目(STS-ZYX-2019028):抗纤缓急颗粒治疗特发性肺纤维化急性加重随机对照探索性临床研究,负责人:张海龙
国家自然科学基金委员会面上项目(81973781):方证对应治疗AECOPD痰热壅肺证患者的生物效应机制与肠道菌群研究,负责人:张海龙。